Lpath, Inc. LPTN, the
industry leader in bioactive-lipid-targeted therapeutics, has received notice
from Pfizer Inc. that Pfizer is currently seeking to divest certain
ophthalmology R&D assets, including Pfizer's exclusive option for a worldwide
license to develop and commercialize Lpath's iSONEP™. Lpath has presented an
offer to Pfizer to reacquire these rights, and Lpath believes that a number of
third parties may have an interest in acquiring these rights as well.
iSONEP is currently being studied by Lpath in a Phase 2 clinical trial as both
monotherapy and adjunctive therapy in wet-AMD patients. A data read-out on the
study is expected in the third quarter of 2014.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in